
IM PGY-3 @RutgersIMRes Clinician Educator Track I Incoming Cardiology Fellow 🫀I Former @Pfizer Vaccines R&D Scientist I 1st Gen I 🥍 🏋️♂️ 🔬☕️
Joined December 2023
- Tweets45
- Following102
- Followers66
- Likes166
Pinned Tweet
Absolutely thrilled to announce I matched at my top choice for Cardiology Fellowship 🫀!
#Match2025
🎉Welcome to our newly matched @Rutgers_card Fellows! 🎉
We’re thrilled to have you join the fellowship!
Thank you to our PD @GerulaChristine and all the faculty for an outstanding interview season!
#Match2026 #FellowMatch #CardioTwitter #cardiologymatch @NJACC #ACCFIT
Navid Radfar retweeted
Hi all,
The Lp(a) HORIZON trial has released topline data and, quite shockingly, missed its primary endpoint.
In other words, lowering Lp(a) in patients with prior MI, stroke or peripheral arterial disease, who were otherwise very well treated for LDL-C, blood pressure, diabetes and other risk factors, did not reduce the primary cardiovascular endpoint.
We obviously need to see the full data before making firm conclusions, and I don’t want to speculate too much without the details.
But this is a big enough result that it is worth summarizing what we know, what we don’t know, and what this may mean for our patients after 20+ years of trying to test the “Lp(a) hypothesis.”
What we know:
1-There are hundreds if not thousands of genetic, epidemiologic and Mendelian-randomization studies showing that elevated Lp(a) is associated with MI, stroke, peripheral arterial disease and aortic stenosis. That body of evidence is very strong.
2-However, much of those data come from community-based populations, often before the era of intensive LDL-C lowering and modern secondary prevention.
3-There has been much less information about how much residual risk Lp(a) carries in someone who has already had an event and is then treated very aggressively.
4-HORIZON may have had some of the best-treated patients of any recent cardiovascular outcomes trial.
Baseline LDL-C was about 65 mg/dL, a measured LDL-C contains the cholesterol carried on Lp(a), so in reality, 15-20 points lower.
5-In patients with very high Lp(a), if you correct LDL-C for Lp(a)-cholesterol, the actual LDL-C carried by LDL particles may have been closer to 45–50 mg/dL, perhaps even lower in some patients.
6-This raises a very basic question:
Can you still demonstrate a major incremental benefit from lowering another apoB-containing particle when the underlying LDL burden has already been driven this low?
What we don’t know:
1-What was the actual corrected LDL-C in these patients? I think it would be extremely informative to directly measure Lp(a)-C and calculate corrected LDL-C. This may tell us a lot about the biological setting in which pelacarsen was being tested.
2- What was the OxPL status? Our prior work has suggested that much of the pro-inflammatory biology associated with Lp(a) is related to its enrichment in oxidized phospholipids. Did OxPL fall? Did patients with higher OxPL derive more benefit? Was Lp(a) concentration actually identifying the patients with the most pathogenic particles?
3- Did we measure the right component of Lp(a) for trial inclusion? We generally measure molar particle concentration. But is molar concentration itself the main driver of risk, or is it partly a surrogate for what the particle carries? Cholesterol? Triglycerides? Oxidized phospholipids? Other proteins? Could two patients with the same Lp(a) concentration have very different Lp(a)-mediated risk? I think this question deserves much more attention.
3- Were the genetic data telling us exactly what we thought they were telling us? The genetic data are extremely compelling, but genetics reflect lifelong exposure. A clinical trial treats patients late in life, often after decades of arterial injury and after an event has already occurred. Those are not necessarily the same experiment. Could there also be some unrecognized biology linked to the LPA locus that we have not completely accounted for? That possibility should at least be considered.
3- Does very low LDL-C modify the Lp(a) risk relationship? Maybe Lp(a) is particularly important when LDL-C is higher, but its contribution becomes smaller once LDL-C is driven to very low levels. Again, we need the data.
4- Does aspirin or other antiplatelet therapy reduce part of the risk associated with Lp(a)? Lp(a) has potentially important prothrombotic effects. Almost everyone in a trial like HORIZON is receiving contemporary antiplatelet therapy. Could that blunt one component of the risk associated with Lp(a)?
5- Why are these patients still having events? This may be one of the most interesting questions of all. These are patients with LDL-C around 65 mg/dL, and perhaps corrected LDL-C substantially lower, yet cardiovascular events continue to occur. What is driving that residual risk? Inflammation? Thrombosis? Plaque burden that is already too advanced? Other lipoprotein characteristics? Something we are not measuring?
6- Do we need to re-examine some basic assumptions about atherosclerosis? We have spent decades focusing heavily on the quantity of circulating lipoproteins. But perhaps lipoproteins are relatively benign until they undergo biological modification in the artery wall. Oxidation may be one of those key modifications. For some patients, the answer may be to remove more particles from the circulation. For others, perhaps the better approach is to prevent their oxidation or block the downstream biological effects of oxidized lipids. The recent difficulties with anti-inflammatory approaches, including IL-6 inhibition, make these mechanistic questions even more interesting.
7- Was there something specific about pelacarsen, the degree or timing of Lp(a) lowering, advanced disease, trial duration, background therapy or patient selection that mitigated a potential benefit? We simply don’t know yet. That is why the detailed results will be so important.
What does this mean for patients today?
If you have already had an MI, stroke or PAD, the immediate lesson is very clear:
1- Get all of your established risk factors treated aggressively.
2- Get LDL-C/apoB very low.
3- Control blood pressure.
4- Control diabetes.
5- Don’t smoke.
6- Use appropriate antiplatelet and other guideline-directed therapies.
HORIZON shows us what modern secondary prevention should look like.
If you have elevated Lp(a) but have never had an event, the genetic and epidemiologic data still suggest increased lifetime risk.
Until the other 4 outcome trials read out, I would continue to treat every modifiable risk factor aggressively.
We should wait for those trials before drawing broad conclusions about the entire field.
I think the story of Lp(a) therapy is beginning, not ending.
We also need to show tremendous respect and gratitude to the patients who participated in HORIZON and to the investigators and companies that invested enormous resources to actually test the Lp(a) hypothesis, to the ultimate benefit to peole with elevated Lp(a) to best guide how to manage risk.
More to come as we go forward.
Proud to share a 2-year passion project of mine: a multi-site Lp(a) screening study in VA and safety-net settings, now published with @AJPCardio 🫀
Grateful to everyone at @RutgersIMRes @RutgersCardio for supporting this endeavor🩺Link below!
@Rutgers_NJMS
#Lpa
#Cardiology
Navid Radfar retweeted
Implementing Lp(a) Screening in Veterans Affairs & Safety Net Settin... sciencedirect.com/science/ar… led by Scarlet Knight 🫀Prevention & Imaging specialist Drs. Erfan Tasdighi, Navad Radfar, Alfonso Waller & Michael Blaha @ErfanTasdighi @navid_radfar @alfonsowallermd #🥍🐦🫀⚽️🎾🏊🏼♀️🏃♀️
Precision #Cardiology is reshaping how we treat almost everything, but stroke prevention in AFib still leans on one score. Our new paper in the American Journal of Cardiovascular Drugs (@SpringerNature) makes the case for something more personal🫀
rdcu.be/fp3al
Navid Radfar retweeted
The Poster Hall at #NLASessions was absolutely electric! A record number of abstracts, incredible research, and so much passion on display. Congratulations to every single presenter who shared their work this weekend!👏
In the midst of all the action, Social Ambassador Dr. Navid Radfar interviewed Dr. Andrew Cyr about one of the hottest topics of the meeting: Lp(a). The future of lipidology is in outstanding hands!
@navid_radfar
#NLASessions #Lipidology #AbstractPresentations #CardiometabolicHealth #PreventiveCardiology
Day 3: Rewriting the Rules for Primary Prevention
Decades of data are clear: the lower the LDL-C, the better. Time to rethink the reactive approach and start lowering sooner. VESALIUS-CV is the first major PCSK9i outcomes trial to push into the pre-event space.
@nationallipid
Excellent session by Dr. @DineshKalra at NLA/EAS joint session on augmenting prevention with imaging. Risk scores like PREVENT predict from surrogates, while imaging detects disease itself — adding real precision for patients these calculators underestimate. 🫀
@nationallipid
Great to hear incoming NLA President @DineshKalra address a clear vision for equitable lipid care for underserved patients through partnership with industry. A mission that hits home with our Lp(a) screening initiative in NJ.
#NLASessions2026
@nationallipid
Excited to share that I've been selected as a 2026 #NLASessions Media Ambassador! I'll be sharing live coverage, key clinical takeaways, and behind-the-scenes moments from the NLA Scientific Sessions in Chicago this June. Stay tuned! @nationallipid
Introducing your 2026 #NLASessions Media Ambassador Team!🌟🤳
This incredible group will be bringing all the action straight to your screens — from hot-topic presentations and clinical insights to behind-the-scenes moments and everything in between. Make sure you're following them to experience #NLASessions live from Chicago!
@CarlosVergaraMD @BinayMd @frankq1368 @navid_radfar
Share YOUR own excitement using our Social Media Toolkit, featuring ready-to-post graphics and captions made just for you.
🔗 lipid.org/meetings/sessions/…
#Lipidology #CardiometabolicHealth #PreventiveCardiology #SocialMediaAmbassador
What an honor to be featured on the front cover of Pulse Magazine, highlighting our local and state-wide initiatives in Lipoprotein(a) screening and management 🫀🩺
@RutgersIMRes
@RutgersCardio
#Lipoproteina
#Lpa
#MedEd
#Cardiotwitter
The Spring/Summer 2026 issue of Pulse Magazine is here! issuu.com/rutgersnjms/docs/p…
Discover inspiring stories from NJMS students, faculty, and alumni—highlighting innovation, community engagement, research, and more. @rutgershealth
Still buzzing after an incredible #ACC26 ⚜️🎷
Grateful for the opportunity to connect with so many great people, exchange ideas, and contribute to the conversation around prevention and precision cardiology 🫀
@ACCinTouch
@RutgersCardio
@RutgersIMRes
#Lpa
#CardioTwitter
Navid Radfar retweeted
Do you know your Lp(a) level?
1 in 5 people have high Lp(a), an inherited risk factor for atherosclerosis, yet less than 5% have been screened.
We've made screening easy. Request your free kit today: CholesterolConnect.org
#LpaAwarenessDay #KnowLpa
Navid Radfar retweeted
Key updates to this guideline include:
➡️ The use of the American Heart Association PREVENT-ASCVD equations to guide primary-prevention and lipid-lowering therapy decisions.
➡️ Testing Lp(a) at least once in a lifetime and selective apolipoprotein B measurement to improve risk assessment and guide treatment
➡️ The return of LDL-C and non-high-density lipoprotein cholesterol treatment goals (with lower targets for higher-risk groups)
➡️ Expanded use of coronary artery calcium scoring to reclassify risk[ME1.1]
✍🏼 @rblument1 @tygluckman @RonBlankstein @PamelaBMorris @pnatarajanmd @AnnMarieNavar @SethShayMartin @APRN_CNS @nyulangone @DrMichaelShapir @kgradneyrd @eugeniagianos @virani_md @KellieMcLain1 @ijeomaheartdoc @SamiaMoraMD @DrHeatherJohn @dmljmd
Navid Radfar retweeted
🙌 Today the 2026 ACC/AHA Guideline on the Management of Dyslipidemia has been released.
📍Key updates shaping contemporary lipid management:
1️⃣ Lp(a) measurement is now recommended at least once in all adults for ASCVD risk assessment.
2️⃣ PREVENT equations replace the Pooled Cohort Equations for estimating 10-year and 30-year ASCVD risk.
3️⃣ LDL-C and non-HDL-C treatment goals return as central therapeutic targets alongside percentage LDL reduction.
4️⃣ Earlier intervention is emphasized to reduce lifelong exposure to atherogenic lipoproteins.
5️⃣ Broader integration of ApoB, CAC scoring, and modern lipid-lowering therapies to refine risk stratification and treatment.
👆 An important step forward in translating decades of lipid research into clinical practice and cardiovascular prevention.
🔓 Open Access
🔗 jacc.org/doi/10.1016/j.jacc.…
@nationallipid
@society_eas
Navid Radfar retweeted
Happening tomorrow!⌛
Join us tomorrow @ 12–1 PM ET for a live webinar on Promoting Lipoprotein(a) Awareness and Testing for Risk Identification Through Outreach and Teaching, led by @navid_radfar.
Gain practical strategies you can apply in your practice right away. Secure your spot: lipid.org/practicalpearls
What an absolute honor! So excited to present insights from our PATRIOT and ACHILLES studies ! 🫀
@RutgersIMRes
@RutgersCardio
#MedEd
#Lpa
Our first Practical Pearl of the year is coming up!🩺
Join us Thursday, Feb. 12 (12–1 PM ET) for a live webinar on Promoting Lipoprotein(a) Awareness and Testing for Risk Identification Through Outreach and Teaching, led by @navid_radfar.
Gain practical strategies you can apply in your practice right away. Register now: lipid.org/practicalpearls
Excited to share outcomes from our Lipoprotein(a) PATRIOT-QI implementation study at @ACCinTouch 2026 🫀
@DeptVetAffairs
@RutgersIMRes
@RutgersCardio
#Lpa
#ACC2026
#PreventiveCardiology
9
445





















